Standard of Care: Protecting Your Child's Immune System
At a Glance
Care for children with Immunodeficiency 89 is individualized: antibody replacement can reduce infections, while PJP prevention, careful vaccine decisions, and specialist monitoring help prevent serious illness. Stem cell transplant is reserved for selected severe cases because it carries risks.
Managing a rare condition like Immunodeficiency 89 (IMD89) requires a proactive and personalized approach. Because this condition was only recently discovered, there is no single “manual” specifically for IKZF3 deficiency [1]. Instead, your child’s immunology team will use established Standard of Care guidelines for Inborn Errors of Immunity (IEI) to protect your child’s health [2].
Replacing What is Missing: Antibody Therapy
Because IMD89 often prevents the body from making its own protective antibodies, many children require Immunoglobulin Replacement Therapy (IgRT) [3][4]. This treatment provides “pooled” antibodies (IgG) from healthy donors to help your child fight off bacteria and viruses [5].
There are two main ways to receive this therapy:
- Intravenous Immunoglobulin (IVIG): This is given through a vein, usually in a hospital or clinic, every 3 to 4 weeks [6]. It allows for a large dose to be delivered at once.
- Subcutaneous Immunoglobulin (SCIG): This is given as a small injection under the skin, often once a week, and can usually be done at home by parents [5][6]. SCIG tends to keep antibody levels more stable and is associated with fewer systemic side effects, though local skin reactions are common [7].
The goal of IgRT is to significantly reduce the number of infections your child experiences [8][9]. It is important to understand what IgRT cannot do: While it helps replace missing antibodies, it does not correct the T-cell defect, nor does it reliably prevent opportunistic infections like PJP.
Preventative Shielding: Prophylaxis
In addition to replacing antibodies, doctors often use medications to prevent specific, dangerous infections from starting. This is called prophylaxis.
A critical focus in IMD89 is preventing Pneumocystis jirovecii pneumonia (PJP), a fungal lung infection that can be very serious in children with T-cell defects [1][10]. The most common preventative medication is Trimethoprim-sulfamethoxazole (often called Bactrim or Septra) [10]. The dosing and schedule are strictly individualized based on your child’s age, weight, kidney function, and immune results [11]. Families must follow the prescribed schedule exactly. Your doctor will monitor your child for side effects like skin rashes or changes in their blood counts or kidney function [11][12].
Considering Curative Options: HSCT
For some children with severe forms of combined immunodeficiency, doctors may discuss Hematopoietic Stem Cell Transplantation (HSCT), also known as a bone marrow transplant. The goal of HSCT is to replace the child’s faulty immune system with a healthy one from a donor [13].
Because IMD89 is exceptionally rare, there is no established IKZF3-specific transplant protocol, and HSCT is not an automatic recommendation [13]. It is an uncommon, expert-center consideration that carries severe risks, including graft-versus-host disease (GVHD), organ toxicity, infertility, serious infection, and treatment-related mortality. Doctors will weigh factors such as the severity of your child’s infections, T-cell function, and the availability of a well-matched donor [14][15][13].
A Note on Vaccines
In children with significant T-cell defects, the immune system may struggle to handle live vaccines (such as the MMR, chickenpox, or live nasal influenza vaccines) [16][2]. Never give a live vaccine without your immunologist’s explicit approval. Inactivated (non-live) vaccines—like the injectable flu shot—are generally safe, but may not produce reliable protection [17]. Furthermore, immunoglobulin therapy can affect the timing or interpretation of some live vaccines. Always consult your immunologist.
Daily Life Precautions
Your child’s care team will help translate the medical plan into daily decisions. This includes establishing strict hand hygiene, ensuring household members are fully vaccinated, and creating a written plan for rapid assessment of fevers or sick contacts.
Common questions in this guide
Why might a child with Immunodeficiency 89 need immunoglobulin replacement therapy?
What is the difference between IVIG and SCIG for IMD89?
Does a child with IMD89 need medicine to prevent PJP?
Are live vaccines safe for a child with Immunodeficiency 89?
When might a stem cell transplant be considered for Immunodeficiency 89?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Antibody treatment options
Would my child need immunoglobulin replacement therapy, and which form would be used?
Infection prevention
Is a medicine to prevent Pneumocystis pneumonia something my child would need?
About vaccines
Which vaccines would be a concern for my child, and who should approve them?
Get notified when new evidence is published on immunodeficiency 89 and autoimmunity.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients.
Kuehn HS, Chang J, Yamashita M, et al.
The Journal of experimental medicine 2021; (218(12)) doi:10.1084/jem.20211118.
PMID: 34694366 - 2
Practice parameter for inborn errors of immunity: What is new in the 2025 update.
Chinen J, Horner CC, Orange JS
The Journal of allergy and clinical immunology 2026; (158(2)):368-373 doi:10.1016/j.jaci.2026.05.014.
PMID: 42208906 - 3
AIOLOS-Associated Inborn Errors of Immunity.
Yamashita M, Morio T
Journal of clinical immunology 2024; (44(6)):128 doi:10.1007/s10875-024-01730-9.
PMID: 38773004 - 4
Immunoglobulin replacement therapies in inborn errors of immunity: a review.
Sil A, Basu S, Joshi V, et al.
Frontiers in pediatrics 2024; (12()):1368755 doi:10.3389/fped.2024.1368755.
PMID: 38425666 - 5
A clinician's guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.
Epland K, Suez D, Paris K
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2022; (18(1)):87 doi:10.1186/s13223-022-00726-7.
PMID: 36180928 - 6
Immunoglobulin therapy for immunodeficiency.
Wilson BE, Freeman CM
Allergy and asthma proceedings 2024; (45(5)):364-370 doi:10.2500/aap.2024.45.240053.
PMID: 39294913 - 7
Effectiveness, Safety, and Treatment Satisfaction of 20% Subcutaneous Immunoglobulin Replacement Therapy in Pediatric Patients with Primary and Secondary Immunodeficiencies.
Sefer AP, Kaya MS
Turkish archives of pediatrics 2025; (60(2)):217-225 doi:10.5152/TurkArchPediatr.2025.24305.
PMID: 40094369 - 8
[Immunoglobulin Replacement Therapy in Antibody Production Defects].
Bernardino A, Abdurrachid N, Varandas C, et al.
Acta medica portuguesa 2026; (39(5)):366-371 doi:10.20344/amp.24119.
PMID: 42104827 - 9
Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
Li Z, Follman K, Freshwater E, et al.
International immunopharmacology 2024; (128()):111447 doi:10.1016/j.intimp.2023.111447.
PMID: 38185032 - 10
ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.
Maertens J, Cesaro S, Maschmeyer G, et al.
The Journal of antimicrobial chemotherapy 2016; (71(9)):2397-404 doi:10.1093/jac/dkw157.
PMID: 27550992 - 11
Evaluation of effectiveness, hyperkalaemia, and hepatotoxicity of trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis jirovecii pneumonia in paediatric patients: A single-centre retrospective study.
Kato H, Hagihara M, Asai N, et al.
International journal of antimicrobial agents 2024; (63(5)):107151 doi:10.1016/j.ijantimicag.2024.107151.
PMID: 38508538 - 12
Low-Dose TMP-SMX for Pneumocystis jirovecii Pneumonia Prophylaxis in Pediatric Solid Organ Transplant Recipients.
Chen JK, Guerci J, Corbo H, et al.
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 2023; (28(2)):123-128 doi:10.5863/1551-6776-28.2.123.
PMID: 37139252 - 13
Hematopoietic Stem Cell Transplantation for Combined Immunodeficiencies, on Behalf of IEWP-EBMT.
Neven B, Ferrua F
Frontiers in pediatrics 2019; (7()):552 doi:10.3389/fped.2019.00552.
PMID: 32039114 - 14
A prospective study on the natural history of patients with profound combined immunodeficiency: An interim analysis.
Speckmann C, Doerken S, Aiuti A, et al.
The Journal of allergy and clinical immunology 2017; (139(4)):1302-1310.e4 doi:10.1016/j.jaci.2016.07.040.
PMID: 27658761 - 15
The challenges presented by haematopoietic stem cell transplantation in children with primary immunodeficiency.
Gennery AR
British medical bulletin 2020; (135(1)):4-15 doi:10.1093/bmb/ldaa017.
PMID: 32676650 - 16
Recommendations for uniform definitions used in newborn screening for severe combined immunodeficiency.
Blom M, Zetterström RH, Stray-Pedersen A, et al.
The Journal of allergy and clinical immunology 2022; (149(4)):1428-1436 doi:10.1016/j.jaci.2021.08.026.
PMID: 34537207 - 17
Vaccination in Primary Immunodeficiency Disorders.
Sobh A, Bonilla FA
The journal of allergy and clinical immunology. In practice 2016; (4(6)):1066-1075 doi:10.1016/j.jaip.2016.09.012.
PMID: 27836056
This page explains supportive care options for a child with Immunodeficiency 89 for educational purposes and is not medical advice. Your child's immunologist should guide decisions about immunoglobulin therapy, infection prophylaxis, vaccines, and transplant evaluation.